CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus The Coalition for Epidemic Preparedness Innovations (CEPI)…
Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses Preclinical data support broadly reactive immunity of VBI-2901 against a panel…
New Phase 1b clinical data of VBI-2905 (monovalent, Beta) demonstrated a well-tolerated safety profile and an encouraging ability to boost and broaden the immune response against the Beta variant New…
New preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern including Beta…
VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19
The Phase 1 portion of the ongoing Phase 1/2 study evaluated one- and two-dose regimens of 5µg of eVLP candidate, VBI-2902a, in 61 healthy adults age 18-54 years After two…
Publication title: “An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose” Publication to be available on pre-print…
Up to $33m of funding will support development of VBI’s enveloped virus-like particle (eVLP) vaccine candidates against COVID-19 variants of concern. Phase 1 clinical study of VBI’s eVLP vaccine candidate,…
Initial data from Phase 1 of the study expected by the end of Q2 2021, subject to rate of enrollment Adaptive Phase 1/2 study supported by previously announced contribution from…
Preclinical hamster challenge study demonstrated robust immunogenicity and efficacy compared to placebo First Phase 1/2 study of VBI-2902 expected to begin in Q1 2021 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI),…
World Vaccine Congress: COVID-19 panel discussion, two oral presentations highlighting Phase 3 Sci-B-Vac® data and VBI-1901 Phase 1/2a data ID Week™: Two e-poster presentations featuring Phase 3 Sci-B-Vac® data VBI…